Tuberculosis Trial Design: FDA/Company Endpoint Talks Go Public At Cmte.
Executive Summary
The approval pathway for drugs to treat multi-drug resistant tuberculosis became somewhat clearer for sponsors as FDA's Anti-Infective Drugs Advisory Committee weighed in on clinical trial endpoints at a June 3 meeting
You may also be interested in...
J&J’s Sirturo Gets Panel Endorsement For Accelerated OK, Even As FDA Broaches Full Approval
FDA’s Anti-Infective Drugs Advisory Committee was fully satisfied with “sputum culture conversion” as a surrogate endpoint for accelerated approval, but turned back a last-minute question from FDA on traditional full approval for the tuberculosis drug bedaquiline.
FDA Encourages TB Drug Development But Wary Of Promoting Resistance
FDA's approach to TB drug development demonstrates the traits Commissioner Margaret Hamburg wants in her agency - transparent, proactive, public health-oriented
FDA Encourages TB Drug Development But Wary Of Promoting Resistance
FDA's approach to TB drug development demonstrates the traits Commissioner Margaret Hamburg wants in her agency - transparent, proactive, public health-oriented